New data reveal that while most women with postpartum depression start antidepressant treatment, many discontinue treatment early—highlighting persistent gaps in postpartum care.
An open-label pilot study suggests that intravenous brexanolone may rapidly reduce psychotic, manic, and depressive symptoms in patients with postpartum psychosis, highlighting a potential new treatment option.
Learn more about the impact of perinatal depression on child neurodevelopment, new rapid-acting treatments for PPD, and new data reshaping how we treat menopausal symptoms.
This week’s list spans antidepressant safety, benefits of psychotropic medication continuation on postpartum self-harm risk, anti-seizure medications and congenital malformations, and new approaches to PPD screening.
This week’s roundup covers prenatal SARS-CoV-2 exposure and child neurodevelopment, cannabis use in pregnancy and related risks, and estradiol-linked mood changes during menopause.
Every week we review the most recent publications in women’s mental health.
Every week we review the most recent publications in women’s mental health.
In this postmarketing surveillance data analysis, excessive sedation and loss of consciousness when receiving brexanolone occurred at lower rates than previously reported in clinical trials.
As of October 2023, the Neurosteroid Intervention for Menopausal and Perimenopausal Depression is no longer recruiting participants. Over the last few years we have heard a great deal about neurosteroids, also known as neuroactive steroids. [...]
The transition to menopause, or perimenopause, represents the passage from reproductive to non-reproductive life. During the perimenopause, women experience irregular menstrual cycles, which reflect the large fluctuations in ovarian hormone [...]
